BioSpace News Archive

The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”

As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.

Kelyniam Global, a maker of custom cranial implants, is pleased to announce that the company has submitted all of the documentation required for establishment as a “Pink Current” filer under the new SEC Rule 15c2-11 ahead of schedule for the September 30, 2021 deadline.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, announced positive data from Part A of its Phase 2 study of THR-149, a plasma kallikrein inhibitor, for the treatment of DME.

CytoReason and Summit Pharmaceuticals International announced that CytoReason has entered the Japanese market, with its technology being utilized by one of Japan’s top pharmaceutical companies.

Regeneron Pharmaceuticals, Inc. announced that a trial assessing investigational REGEN-COV™ in patients hospitalized with COVID-19 met its primary endpoint.

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba ® ) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis.

Valbiotis, a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, publishes its financial report for the first half of 2021 and provides an update on the Company’s progress.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announce the participation of members of the company’s senior management in three investor and scientific conferences during October 2021.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported data published in the peer reviewed Journal of Wound Care, indicating that the company’s Nexodyn acid-oxidizing solution, developed with APR’s proprietary Tehclo technology, was found to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers.